The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ESO-T01 delivers its first four multiple myeloma case reports.
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
PD-(L)1 x VEGF bispecifics prove a big draw.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
